Thursday, January 28, 2021 7:20:45 AM
BY GlobeNewswire
— 7:00 AM ET 01/28/2021
DELRAY BEACH, Fla., Jan. 28, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. ( AZRX) (“AzurRx” or the “Company”) , a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, today announced the completion of patient enrollment in the first cohort of the Phase 2b OPTION 2 extension study evaluating immediate-release capsules of MS1819 for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).
The Phase 2b OPTION 2 trial extension arm is currently dosing patients at clinical trial sites in the U.S. and Europe who have participated in the previous arms of the OPTION 2 trial. The goal of the MS1819 clinical program is to provide cystic fibrosis patients with a safe and effective therapy to control EPI, a debilitating gastrointestinal condition common to patients with cystic fibrosis that can lead to a chronic nutritional deficiency. For cystic fibrosis patients, maintaining proper nutritional levels is essential to ensure healthy growth, weight management and good lung function.
James Sapirstein, President and Chief Executive Officer of AzurRx BioPharma ( AZRX), stated, “The extension arm of the Phase 2b OPTION 2 trial is providing us with an opportunity to determine both the optimized dosage and delivery mechanism of MS1819. We have fully enrolled the most important cohort of the extension study and would like to thank both our clinical collaborators and patients for their continued participation in the study. We continue to be encouraged by the absence of any reports of serious adverse events to date, and eagerly look forward to reporting topline results from this trial in Q1 2021.”
OPTION 2 Extension Study
The Phase 2b OPTION 2 study is an open-label, multi-center, crossover clinical trial designed to investigate the safety, tolerability, and efficacy of MS1819 in a head-to-head comparison against the current standard of care for EPI, porcine pancreatic enzyme replacement therapy (PERT). The primary efficacy endpoint is the coefficient of fat absorption (CFA). AzurRx BioPharma ( AZRX) initiated the additional study arm, the Phase 2b OPTION 2 extension trial, to identify both the optimal dose and the optimal delivery method for MS1819 using immediate-release capsules at higher dose levels than previous early-stage clinical trials.
To date, there have been no serious adverse events reported during either the Phase 2b OPTION 2 trial or its extension arm. The Phase 2b OPTION 2 extension trial is enrolling volunteers 18 years or older at trial sites in the U.S. and Poland who have completed the OPTION 2 crossover trial at higher dose levels relative to the previous OPTION 1 trial. Trial participants will be treated with MS1819 over a two-week-period. AzurRx BioPharma ( AZRX) expects to report topline data by the end of first quarter 2021.
Recent FWBI News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 09:10:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 11:00:16 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 08:05:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/23/2024 09:00:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/22/2024 09:28:05 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 12:05:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 12:00:33 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 01:46:33 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 09:20:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 02:54:33 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 08:16:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:05:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2024 12:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2024 06:34:36 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 06/24/2024 12:03:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 08:30:18 PM
- Form PRER14A - Preliminary Proxy Soliciting materials • Edgar (US Regulatory) • 06/17/2024 09:23:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 06/14/2024 09:15:44 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 06/11/2024 04:15:09 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 09:15:42 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/31/2024 09:25:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/30/2024 09:32:34 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/30/2024 09:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 11:16:09 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM